The Proceedings of the American Thoracic Society 1:264-268 (2004)
© 2004 The American Thoracic Society
Corticosteroid Resistance in Airway Disease
Peter J. Barnes
National Heart and Lung Institute, Imperial College, London, United Kingdom
Correspondence and requests for reprints should be addressed to Professor P. J. Barnes, D.M., D.Sc., F.R.C.P., National Heart and Lung Institute, Imperial College, Dovehouse Street, London SW3 6LY, UK. E-mail: p.j.barnes{at}imperial.ac.uk
Resistance to the antiinflammatory effects of corticosteroids is very uncommon in asthma but common in chronic obstructive pulmonary disease. Recent understanding of the molecular mechanisms involved in the antiinflammatory actions of corticosteroids has revealed that there are several possible mechanisms for corticosteroid resistance. Certain cytokines activate p38 mitogen-activated protein kinase, which may interfere with the nuclear localization of glucocorticoid receptors (GRs). In other patients, nuclear localization of GR is normal but there is a reduction in acetylation of a lysine residue in histone-4, thus leading to impaired activation of certain antiinflammatory genes. In chronic obstructive pulmonary disease and severe asthma, oxidative stress may reduce the activity and expression of certain histone deacetylases and therefore interfere with the antiinflammatory action of corticosteroids. These mechanisms suggest that there may be several therapeutic approaches to treating corticosteroid resistance in the future, including antioxidants, p38 mitogen-activated protein kinase inhibitors, and theophylline, which activates histone deacetylases.
Key Words: steroid resistance asthma chronic obstructive pulmonary disease histone deacetylase
This article has been cited by other articles:

|
 |

|
 |
 
Y. Nakamaru, C. Vuppusetty, H. Wada, J. C. Milne, M. Ito, C. Rossios, M. Elliot, J. Hogg, S. Kharitonov, H. Goto, et al.
A protein deacetylase SIRT1 is a negative regulator of metalloproteinase-9
FASEB J,
September 1, 2009;
23(9):
2810 - 2819.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Gaga, E. Zervas, and P. Chanez
Update on severe asthma: what we know and what we need
Eur. Respir. Rev.,
June 1, 2009;
18(112):
58 - 65.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. D. Campbell, L. Borish, T. Haselkorn, L. Rasouliyan, J. H. Lee, S. E. Wenzel, S. D. Sullivan, and on behalf of the TENOR Study Group
The response to combination therapy treatment regimens in severe/difficult-to-treat asthma
Eur. Respir. J.,
November 1, 2008;
32(5):
1237 - 1242.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Braganza, R. Chaudhuri, and N. C. Thomson
Review: Treating patients with respiratory disease who smoke
Therapeutic Advances in Respiratory Disease,
April 1, 2008;
2(2):
95 - 107.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
O. Tliba, G. Damera, A. Banerjee, S. Gu, H. Baidouri, S. Keslacy, and Y. Amrani
Cytokines Induce an Early Steroid Resistance in Airway Smooth Muscle Cells: Novel Role of Interferon Regulatory Factor-1
Am. J. Respir. Cell Mol. Biol.,
April 1, 2008;
38(4):
463 - 472.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L.-b. Li, D. Y. M. Leung, M. J. Strand, and E. Goleva
ATF2 impairs glucocorticoid receptor mediated transactivation in human CD8+ T cells
Blood,
September 1, 2007;
110(5):
1570 - 1577.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Chanez and P. Godard
Is difficult asthma still clinically meaningful?
Eur. Respir. J.,
November 1, 2006;
28(5):
897 - 899.
[Full Text]
[PDF]
|
 |
|
Copyright © 2004 by the American Thoracic Society.
|
|
|